Congress is turning back again to managed-care reform, with Democrats and Republicans trying anew to forge a bipartisan consensus on issues such as: what options exist for a cancer patient whose health insurance company refuses to cover a quasi-
Congress is turning back again to managed-care reform, withDemocrats and Republicans trying anew to forge a bipartisan consensuson issues such as: what options exist for a cancer patient whose healthinsurance company refuses to cover a quasi-experimental treatment. Thatparticular possibility is addressed by the Kennedy-McCain Bipartisan PatientProtection Act of 2001, which is getting support from both sides of the aisle.When an insurance company denies payment for a particular cancer treatment, thepatient could sue the insurance company and the employer for up to $5 million inpunitive damages and an unlimited amount of economic or noneconomic damages infederal court. "Medical necessity" lawsuits, which are a slightlydifferent issue, would be restricted to state courts with damages allowed up tothe limit of that state’s law. Of course, concern about a potentialproliferation of lawsuits is what killed passage of any managed-care legislationin the last session of Congress. The Kennedy-McCain bill (authored by Sen. TedKennedy, D-Mass, and Sen. John McCain, R-Ariz) steps back slightly from some ofthe right-to-sue provisions that Democrats were pushing last year. But the billgoes further than many Republicans were willing to go in 2000.
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Oncology Peer Review On-The-Go: Cancer Care Management During the COVID-19 Pandemic
October 28th 2020The newest episode of Oncology Peer Review On-The-Go speaks with 2 authors of an article from the October Issue of the journal ONCOLOGY focusing on effective cancer care management during the coronavirus pandemic.